Hereditary Angioedema
Explore practical approaches to recognising and managing hereditary angioedema (HAE) to optimise treatment outcomes and improve quality of life for patients living with the disease.
Discover three breakthrough HAE treatments approved in 2025, offering new hope for hereditary angioedema care with improved prevention and treatment options.
Managing hereditary angioedema effectively remains a significant challenge, but recent clinical trials presented at EAACI 2024, in Valencia, Spain, have shown promising advancements in treatment options.
The SPRING Study (NCT04070326) was a phase 3 study that investigated the safety, pharmacokinetics, and pharmacodynamics of lanadelumab for prevention of hereditary angioedema (HAE) attacks in children. touchIMMUNOLOGY were delighted to speak with Dr. William R. Lumry (UT Southwestern Medical Center, ...
Hereditary angioedema (HAE) is a rare genetic disease that reduces C1 inhibitor levels and impacts the regulation of several pathways involved in dilation of the blood vessels and results in recurrent episodes of severe swelling. touchIMMUNOLOGY were delighted to speak ...
The ENABLE study (ClinicalTrials.gov Identifier: NCT04130191) is an observational study, investigating the effectiveness of lanadelumab in real-life use in patients with hereditary angioedema with C1 inhibitor deficiency (HAE-C1-1NH). touchIMMUNOLOGY were delighted to speak with Dr. Andreas Recke (...
Hereditary angioedema with C1-inhibitor deficiency (HAE-C1-INH) is a rare disease resulting in unpredictable attacks of swelling under the skin. touchIMMUNOLOGY were delighted to speak with Dr. Andreas Recke (University of Lübeck, Lübeck, Germany) around the health ...
touchIMMUNOLOGY joins Dr Sorena Kiani (Barts Health NHS Trust, London, UK) to discuss the efficacy and safety of berotralstat in the treatment of hereditary angioedema. Questions 1. What are the unmet needs in the treatment of hereditary angioedema (HAE)? (00:17-01:53) 2. What ...
touchIMMUNOLOGY caught up with Jonathan Bernstein (University of Cincinnati; Bernstein Allergy Group, Bernstein Clinical Research Center, Cincinnati, OH, USA) to discuss the findings from the HELP study, investigating lanadelumab for the prevention of hereditary angioedema (HAE) attacks. The abstract ‘Efficacy ...
touchIMMUNOLOGY caught up with Jonathan Bernstein (University of Cincinnati; Bernstein Allergy Group, Bernstein Clinical Research Center, Cincinnati, OH, USA) to discuss the prevalence of hereditary angioedema, lanadelumab as a treatment option, and the current challenges faced by patients. The abstract ‘...
Log into your Touch Account
Keep track of your clinical interests and newsletter subscriptions.
Sign up with an Email
Or use a .
Register now for FREE access
Already registered? Login below.
